Aurobindo Pharma jumps as its arm gets US FTC`s nod for acquiring 100% of membership interest in Lannett
Aurobindo Pharma is currently trading at Rs. 1471.40, up by 28.35 points or 1.96% from its previous closing of Rs. 1443.05 on the BSE.
The scrip opened at Rs. 1461.95 and has touched a high and low of Rs. 1480.00 and Rs. 1447.60 respectively. So far 109274 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1550.00 on 21-May-2026 and a 52 week low of Rs. 1017.00 on 02-Sep-2025.
Last one week high and low of the scrip stood at Rs. 1,480.00 and Rs. 1391.40 respectively. The current market cap of the company is Rs. 84658.23 crore.
The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.11% and 7.08% respectively.
Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA Inc. has received the necessary approval from US Federal Trade Commission (FTC) for the acquisition of the 100% of membership interest in Lannett Company LLC (Lannett) from Lannett Seller Holdco, Inc.
Earlier, Aurobindo Pharma USA Inc had entered into a definitive agreement with Lannett Seller Holdco Inc for the same. The transaction aligns with the company’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities.
Through this acquisition, the company will gain access to: a complementary portfolio of profitable products, a growing Contract Development and Manufacturing Organization (CDMO) business, and a U.S.-based manufacturing facility with significant excess capacity (425k sq. ft facility with around 3.6bn doses capacity) and with potential for further expansion. The cost of said acquisition is based on an enterprise value of $250 million (Rs 2185 crore) on a cash free debt free basis and including normalized levels of working capital.
